BIVI (BioVie Inc) Prakiraan volume dodolan

Logo grafis BioVie Pharma (BIVI)

BioVie Inc. is scaling clinical trials of inflammation inhibitors to combat Parkinson's and Alzheimer's diseases. The business's revenues are based on bringing treatments for cirrhotic ascites to market. The company's future sales trajectory reflects asset dynamics, where the 0.00 mark indicates the current state. The development of innovative molecules for the correction of cellular metabolism defines the firm's current direction of pharmacological research.

BIVI - Dodolan mangsa ngarep perusahaan biovieinc.com ing rentang 04.07.2022 - 15.11.2026

Rincian analitis perusahaan BioVie Inc. (BIVI)

- nilai saham lan prakiraan konsensus rega:
Analisis dhasar perusahaan:BioVie
Sampel barang BioVie Pharma

For BioVie Inc., which possesses high scientific authority in the therapy of neurodegenerative pathologies, this metric links market value to future earnings. By analyzing the company's expected sales volume, an investor can see the ratio of current capitalization to potential revenue from the commercialization of molecules. This indicator's trend reflects the market's revaluation of assets, allowing for an objective determination of the entry point. High confidence from clinics makes such forecasts more substantiated.